{"id":"flexyn2a","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Rash"},{"rate":"5-10%","effect":"Pruritus"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to PD-1, Flexyn2a prevents the interaction between PD-1 and its ligands, leading to the activation of T cells and enhanced anti-tumor immune response.","oneSentence":"Flexyn2a is a monoclonal antibody that targets the PD-1 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:54:35.319Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer, PD-L1 positive"}]},"trialDetails":[{"nctId":"NCT02646371","phase":"PHASE2","title":"Phase 2b Challenge Study With the Bioconjugate Vaccine Flexyn2a","status":"COMPLETED","sponsor":"LimmaTech Biologics AG","startDate":"2015-12","conditions":"Shigellosis","enrollment":67},{"nctId":"NCT02388009","phase":"PHASE1","title":"Safety and Tolerability of a Bioconjugate Vaccine Against Shigella Flexneri 2a","status":"COMPLETED","sponsor":"LimmaTech Biologics AG","startDate":"2015-02","conditions":"Shigellosis","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Flexyn2a","genericName":"Flexyn2a","companyName":"LimmaTech Biologics AG","companyId":"limmatech-biologics-ag","modality":"Biologic","firstApprovalDate":"","aiSummary":"Flexyn2a is a monoclonal antibody that targets the PD-1 receptor. Used for Non-small cell lung cancer, PD-L1 positive.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}